Innocare Pharma Limited(688428),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

688428 Innocare Pharma Limited

Closed 12-12 15:00:00

24.94

+1.11

+4.66%

High25.21	Low23.77	Vol8.47M
Open24.11	D1 Closing23.83	Amplitude6.04%
Mkt Cap44.02B	Tradable Cap6.68B	Total Shares1.76B
T/O207.00M	T/O Rate3.16%	Tradable Shares268.00M
P/B6.6	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"Innocare Pharma Limited","latestPrice":24.94,"timestamp":1765522800000,"preClose":23.83,"halted":0,"volume":8467597,"delay":0,"changeRate":0.0466,"floatShares":268000000,"shares":1764999999,"eps":-0.1302,"marketStatus":"Closed","change":1.11,"latestTime":"12-12 15:00:00","open":24.11,"high":25.21,"low":23.77,"amount":207000000,"amplitude":0.0604,"askPrice":24.94,"askSize":64,"bidPrice":24.91,"bidSize":37,"shortable":0,"etf":0,"ttmEps":-0.1302,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":23.83,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":26.21,"lowLimit":21.45,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1764643952,"isCdr":false,"pbRate":6.6,"roa":"--","roe":"--","epsLYR":-0.26,"committee":-0.624801,"marketValue":44010000000,"turnoverRate":0.0316,"status":0,"afterMarket":{"amount":0,"volume":0,"close":24.94,"buyVolume":0,"sellVolume":0,"time":1765524839585,"indexStatus":"Closed 12-12 15:30:00","preClose":23.83},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"INNOCARE","latestPrice":14.27,"timestamp":1765526889009,"preClose":13.58,"halted":0,"volume":8347357,"delay":0,"premium":"-48.13"},"floatMarketCap":6693000000},"requestUrl":"/m/hq/s/688428/wiki","defaultTab":"wiki","newsList":[{"id":"2591668987","title":"InnoCare Pharma Wins Approval to Start Phase III Trial of Orelabrutinib for SLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2591668987","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591668987?lang=en_us&edition=fundamental","pubTime":"2025-12-14 17:50","pubTimestamp":1765705812,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. has received regulatory approval from the Center for Drug Evaluation  to conduct a phase III registrational clinical trial of orelabrutinib for the treatment of systemic lupus erythematosus . This approval follows the successful achievement of the primary endpoint in the phase IIb study, where orelabrutinib demonstrated outstanding efficacy and a well-tolerated safety profile in SLE patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nNDL5JFyfG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU0314104364.USD","SG9999014039.USD","BK4585","688428","BK4112","BK0239","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2591668697","title":"InnoCare Announces Achievement of Primary Endpoint in Phase Iib Study of Orelabrutinib for Sle and Approval of Phase Iii Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591668697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591668697?lang=en_us&edition=fundamental","pubTime":"2025-12-14 17:50","pubTimestamp":1765705800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nTUA9KK225:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688428"],"gpt_icon":0},{"id":"1188661956","title":"Innocare Pharma Limited (688428.SH): Orelabrutinib Meets Primary Endpoint in Phase IIb Study for Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=1188661956","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188661956?lang=en_us&edition=fundamental","pubTime":"2025-12-14 16:30","pubTimestamp":1765701012,"startTime":"0","endTime":"0","summary":"Innocare Pharma Limited (688428.SH) announced that its self-developed BTK inhibitor, orelabrutinib, has met the primary endpoint in a Phase IIb clinical study for treating systemic lupus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","09969","BK1574","688428","BK1161"],"gpt_icon":0},{"id":"1178739772","title":"HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1178739772","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178739772?lang=en_us&edition=fundamental","pubTime":"2025-12-12 14:10","pubTimestamp":1765519826,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09969","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2590751418","title":"BRIEF-Innocare Pharma Announces Approval Of Zurletrectinib By China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590751418","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590751418?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:36","pubTimestamp":1765463779,"startTime":"0","endTime":"0","summary":"BRIEF-Innocare Pharma Announces Approval Of Zurletrectinib By China's NMPADec 11 (Reuters) - InnoCare Pharma Ltd 688428.SS:APPROVAL OF ZURLETRECTINIB BY CHINA'S NMPAFurther company coverage: 688428.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH073:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2590597224","title":"InnoCare Pharma Gets China Nod for Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2590597224","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590597224?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:08","pubTimestamp":1765451311,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SHA:688428, HKG:9969) obtained approval for zurletrectinib from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.The drug is for the treatment of adult and adolescent patients with solid tumors harboring NTRK gene fusions.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK0239","BK1161","BK1574","688428"],"gpt_icon":0},{"id":"2590117592","title":"InnoCare Pharma Ltd - Approval of Zurletrectinib by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590117592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590117592?lang=en_us&edition=fundamental","pubTime":"2025-12-11 18:34","pubTimestamp":1765449285,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH073:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2590763493","title":"InnoCare Pharma Showcases Over 20 Orelabrutinib Studies Highlighting Efficacy in Lymphoma at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590763493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590763493?lang=en_us&edition=fundamental","pubTime":"2025-12-10 09:22","pubTimestamp":1765329770,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. announced that over 20 studies of its novel BTK inhibitor, orelabrutinib, were presented at the 67th Annual Meeting of the American Society of Hematology . The presentations included efficacy and safety data for orelabrutinib in multiple lymphoma types, such as marginal zone lymphoma , mantle cell lymphoma , chronic lymphocytic leukemia /small lymphocytic lymphoma , primary central nervous system lymphoma , and diffuse large B-cell lymphoma . Highlights included preliminary results from phase II studies in untreated MZL, combination regimens in DLBCL, and real-world analyses. An oral presentation reported that early cerebrospinal fluid ctDNA and MYD88 clearance during orelabrutinib-based induction therapy in newly diagnosed PCNSL may provide superior predictive and prognostic information compared to PET-CT. The studies were presented at the 2025 ASH Annual Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLbKYGRx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","688428","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK0239","SG9999014021.USD","NDAQ","SG9999014039.USD","BK4588"],"gpt_icon":0},{"id":"2590393516","title":"InnoCare Pharma Reports High Remission Rates for Mesutoclax in Relapsed/Refractory Lymphoma and Leukemia Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2590393516","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590393516?lang=en_us&edition=fundamental","pubTime":"2025-12-09 10:05","pubTimestamp":1765245902,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1Yx8Ss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","NDAQ","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","BK4588","SG9999014021.USD","688428","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU0314104364.USD"],"gpt_icon":0},{"id":"2586227107","title":"InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis","url":"https://stock-news.laohu8.com/highlight/detail?id=2586227107","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586227107?lang=en_us&edition=fundamental","pubTime":"2025-11-28 09:55","pubTimestamp":1764294935,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. has announced the dosing of the first patient in a global Phase II clinical trial of its TYK2 inhibitor, Soficitinib , for the treatment of prurigo nodularis in China. Soficitinib is being developed for several T-cell related autoimmune disorders, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, prurigo nodularis, and urticaria. The company previously presented data from a Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis, demonstrating efficacy and a strong safety profile, at the American Academy of Dermatology  Annual Meeting. The prurigo nodularis market was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 2034.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL34LJDg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4588","BK4112","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","BK0239","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","688428"],"gpt_icon":0},{"id":"2586710062","title":"InnoCare Announces First Patient Dosed in the Global Phase Ii Clinical Trial of Tyk2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis","url":"https://stock-news.laohu8.com/highlight/detail?id=2586710062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586710062?lang=en_us&edition=fundamental","pubTime":"2025-11-28 09:55","pubTimestamp":1764294921,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nTUA57TZYY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2583593535","title":"InnoCare Pharma Logs Over 34 Million Yuan in Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593535","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593535?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040603,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  recorded an attributable loss of 34.3 million yuan in the third quarter of 2025, a Thursday Hong Kong bourse filing said.Loss per share for the three months stood at 0.02 yuan, with operating revenue rising 38% to 383.9 million yuan.The higher revenue was due to an increase in the sales revenue of core product orelabrutinib, as well as the upfront payment under an exclusive license agreement with Prolium Bioscience.For the nine months ended Sept. 30, attributable loss reached 64.4 million yuan, while operating revenue surged 60% to 1.12 billion yuan.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK0239","BK1161","688428","BK1574"],"gpt_icon":0},{"id":"2583566116","title":"BRIEF-Innocare Pharma Logs 9M Gross Margin 88.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583566116","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583566116?lang=en_us&edition=fundamental","pubTime":"2025-11-13 18:55","pubTimestamp":1763031318,"startTime":"0","endTime":"0","summary":"BRIEF-Innocare Pharma Logs 9M Gross Margin 88.8%Nov 13  - InnoCare Pharma Ltd 688428.SS:9M GROSS MARGIN 88.8%JANUARY TO SEPTEMBER, TOTAL OPERATING REVENUE OF RMB1.12 BILLIONJANUARY TO SEPTEMBER, NET LOSS OF RMB72 MILLIONFurther company coverage: 688428.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX109F3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2583563813","title":"InnoCare Pharma Files Directors List with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2583563813","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583563813?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:57","pubTimestamp":1763027836,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. The Board consists of Executive Directors Dr. Jisong Cui  and Dr. Renbin Zhao; Non-executive Directors Dr. Yigong Shi and Mr. Ronggang Xie; and Independent Non-executive Directors Ms. Lan Hu, Dr. Dandan Dong, and Prof. Kunliang Guan. Committee memberships are as follows: - Audit Committee: Ms. Lan Hu , Mr. Ronggang Xie , Dr. Dandan Dong  - Compensation Committee: Ms. Lan Hu , Dr. Jisong Cui , Dr. Dandan Dong  - Nomination Committee: Dr. Jisong Cui , Dr. Dandan Dong , Prof. Kunliang Guan . Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief on Nove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL6RKc7w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2583156803","title":"InnoCare Pharma 9M Gross Margin 88.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583156803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583156803?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:52","pubTimestamp":1763027575,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX109F3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2583050568","title":"InnoCare Pharma -  January to September, Total Operating Revenue of RMB1.12 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583050568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583050568?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:52","pubTimestamp":1763027575,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX109F3F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688428"],"gpt_icon":0},{"id":"1102963016","title":"Innocare Pharma Limited (688428.SH) Reports Q3 Results with Net Loss of 64.41 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1102963016","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102963016?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:16","pubTimestamp":1763025391,"startTime":"0","endTime":"0","summary":"Innocare Pharma Limited (688428.SH) released its third-quarter financial report for 2025, showing revenue of 1.115 billion yuan for the first nine months, a year-on-year increase of 59.85%. However,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","09969","BK1161","BK1574","BK0239"],"gpt_icon":0},{"id":"2579534324","title":"InnoCare Pharma Board to Review Third Quarterly Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579534324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579534324?lang=en_us&edition=fundamental","pubTime":"2025-10-31 16:33","pubTimestamp":1761899624,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. will hold a board meeting on Thursday, 13 November 2025 to consider and approve the unaudited third quarterly results of the company and its subsidiaries for the nine months ended 30 September 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDLMDX89:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2579488863","title":"InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794","url":"https://stock-news.laohu8.com/highlight/detail?id=2579488863","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579488863?lang=en_us&edition=fundamental","pubTime":"2025-10-31 08:30","pubTimestamp":1761870612,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. has announced the dosing of the first patient in a clinical trial of its novel B7-H3 targeted antibody-drug conjugate , ICP-B794, in China. ICP-B794 is developed from InnoCare's proprietary ADC platform and consists of a humanized anti-B7-H3 monoclonal antibody conjugated to an in-house developed payload via a protease-cleavable linker. The therapy is designed to precisely target tumor cells while minimizing off-target effects and is being evaluated for the treatment of various solid tumors, including lung, esophageal, nasopharyngeal, head and neck, and prostate cancers. Preclinical studies have shown superior anti-tumor activity and significant tumor-killing effects compared to other ADCs. According to the announcement, there are currently no B7-H3 targeted therapies approved for marketing globally. The results of this clinical trial have not yet been presented and will be made available in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL67vD6G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2095319765.USD","LU0314104364.USD","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","BK4588","688428","LU2210150020.SGD","NDAQ","BK0239","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2579210001","title":"InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC Icp-B794 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2579210001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579210001?lang=en_us&edition=fundamental","pubTime":"2025-10-31 08:30","pubTimestamp":1761870602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUA1J0C0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688428"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","stockEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":-0.0083},{"period":"3month","weight":-0.1656},{"period":"6month","weight":-0.1061},{"period":"1year","weight":0.8007},{"period":"ytd","weight":1.0309}],"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","perCapita":"14274股","boardName":"医药制造业","registeredCapital":"0万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。","serverTime":1765733687889,"listedPrice":11.03,"stockholders":"18800人(较上一季度增加Infinity%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Innocare Pharma Limited(688428),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Innocare Pharma Limited(688428) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Innocare Pharma Limited,688428,Innocare Pharma Limited股票,Innocare Pharma Limited股票老虎,Innocare Pharma Limited股票老虎国际,Innocare Pharma Limited行情,Innocare Pharma Limited股票行情,Innocare Pharma Limited股价,Innocare Pharma Limited股市,Innocare Pharma Limited股票价格,Innocare Pharma Limited股票交易,Innocare Pharma Limited股票购买,Innocare Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Innocare Pharma Limited(688428),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Innocare Pharma Limited(688428) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}